The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto, Paolo Bruzzi, Alexander Eggermont, Omid Hamid, Hussein A. Tawbi, Alexander Van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone

Research output: Contribution to journalArticle


The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Original languageEnglish
Article number148
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - May 10 2019



  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • BRAF inhibitor
  • Immunotherapy
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Targeted therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this